Aurobindo Pharma USA receives FTC approval for Lannett acquisition
Acquisition to expand Aurobindo USA's portfolio of complex generics and U.S. manufacturing capacity
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
complex generics
DoP implements PLI scheme for pharmaceuticals with a financial outlay of Rs 15,000 cr
The scheme provides a financial incentive to 55 selected applicants for manufacturing of identified products under three…
Credit profile of Indian pharma cos to remain healthy in FY2025 despite moderation in revenue…
Revenue growth to moderate to 8-10 per cent in FY2025, post a healthy 13-14 per cent YoY expansion in FY2024
Pharma industry headwinds in remission: ICRA
Revenues of ICRA’s sample set to grow by 7-9 per cent in FY2024; OPM to stabilise at 20.5-21.5 per cent in FY2024
Stability of input costs, specialty product launches to support performance of Indian pharma…
Revenues of ICRA’s sample set expected to grow by 6-8 per cent in FY2023 and FY2024; operating profit margins to stabilise at…
The (pharma) sector is learning to create capabilities in innovative R&D rapidly
Dr Sanjay Kumar Jain, President - India Operations, Amneal Pharmaceuticals speaks about the emerging trends in pharma R&D,…
Amneal completes acquisition of Kashiv Specialty Pharmaceuticals
Kashiv Specialty Pharmaceuticals is focused on the development of complex generics, innovative drug delivery platforms and novel…
Innovation – The next frontier
Alok Ghosh, Ex-President - Global Technical Operations, Lupin, underscores the importance of creating a conducive environment to…
Slayback Pharma announces investment of $50 million by The Everstone Group
The new capital will be used to expand and accelerate further Slayback’s pipeline of complex generic and specialty pharmaceutical…